Drug Profile


Alternative Names: AMG-139; Anti-IL-23 MAb - Amgen; MEDI-2070

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Amgen; AstraZeneca
  • Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease
  • No development reported Psoriasis

Most Recent Events

  • 01 Dec 2016 AstraZeneca completes a phase IIa trial for Crohn's disease in USA, Canada, France, Italy, Poland, Germany, Czech Republic, Hungary and Spain (NCT01714726)
  • 03 Oct 2016 Brazikumab licensed to Allergan worldwide
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Crohn's-disease in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top